Search results for "Oncology and hematology"

showing 10 items of 15 documents

Injury-activated glial cells promote wound healing of the adult skin in mice

2018

Cutaneous wound healing is a complex process that aims to re-establish the original structure of the skin and its functions. Among other disorders, peripheral neuropathies are known to severely impair wound healing capabilities of the skin, revealing the importance of skin innervation for proper repair. Here, we report that peripheral glia are crucially involved in this process. Using a mouse model of wound healing, combined with in vivo fate mapping, we show that injury activates peripheral glia by promoting de-differentiation, cell-cycle re-entry and dissemination of the cells into the wound bed. Moreover, injury-activated glia upregulate the expression of many secreted factors previously…

0301 basic medicine10017 Institute of AnatomyGeneral Physics and AstronomyTransforming Growth Factor betaMedicinelcsh:ScienceMyofibroblastsCells CulturedSkinMice KnockoutMultidisciplinaryintegumentary systemSOXE Transcription FactorsQCell CycleCell Differentiation3100 General Physics and AstronomyCell biologyMice Inbred DBACutaneous woundMyofibroblastNeurogliaSignal TransductionMice 129 StrainScienceMice Transgenic610 Medicine & health1600 General ChemistryGeneral Biochemistry Genetics and Molecular BiologyArticle03 medical and health sciencesParacrine signallingDownregulation and upregulationIn vivoFate mapping1300 General Biochemistry Genetics and Molecular BiologyAnimalsHumansEpithelial proliferationWound Healingbusiness.industryGene Expression ProfilingGeneral ChemistryMice Inbred C57BL030104 developmental biology10032 Clinic for Oncology and Hematology570 Life sciences; biologylcsh:QWound healingbusiness
researchProduct

Changing the education paradigm in oncology: ESO masterclass, 17 years of continuous success

2020

In this review, we summarize the history of the 41 Masterclasses in Clinical Oncology (MCO) organized by ESO or ESO-ESMO during the last 17 years. MCOs have been held in five different geographical regions including: a) Central Europe, b) Eastern Europe and Balkans, c) Baltic and Euroasia, d) Arab World and Southern European Countries and e) Latin America. More than 2.000 young oncologists have attended and more than 250 distinguished faculty members have actively participated. The program exposes students to sessions covering all major tumors ("big killers") and to spotlights updating information on various important cancers and related topics. Participants are able to present their own cl…

0301 basic medicineLatin Americans2720 HematologyLearning assessment610 Medicine & healthMedical Oncology03 medical and health sciences0302 clinical medicineSurveys and QuestionnairesMedicineTumor boardHumansSocieties MedicalClinical OncologyOncologistsMedical educationbusiness.industryTeachingHematologyTest (assessment)Europe030104 developmental biologyOncologyEducation Medical Graduate030220 oncology & carcinogenesis10032 Clinic for Oncology and Hematology2730 OncologyClinical casebusiness
researchProduct

Prevalence and Clinical Outcomes for Patients With ALK-Positive Resected Stage I to III Adenocarcinoma: Results From the European Thoracic Oncology P…

2014

Purpose The prevalence of anaplastic lymphoma kinase (ALK) gene fusion (ALK positivity) in early-stage non–small-cell lung cancer (NSCLC) varies by population examined and detection method used. The Lungscape ALK project was designed to address the prevalence and prognostic impact of ALK positivity in resected lung adenocarcinoma in a primarily European population. Methods Analysis of ALK status was performed by immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH) in tissue sections of 1,281 patients with adenocarcinoma in the European Thoracic Oncology Platform Lungscape iBiobank. Positive patients were matched with negative patients in a 1:2 ratio, both for IHC and for …

AdultMaleCancer Researchmedicine.medical_specialtyPathologyLung NeoplasmsPopulation610 Medicine & healthAdenocarcinoma of LungAdenocarcinomaGastroenterologyCohort Studies10049 Institute of Pathology and Molecular Pathologyhemic and lymphatic diseasesThoracic OncologyInternal medicinePrevalencemedicineHumansAnaplastic lymphoma kinase1306 Cancer ResearchAnaplastic Lymphoma KinaseLung cancereducationIn Situ Hybridization FluorescenceAgedNeoplasm Stagingeducation.field_of_studyLungbusiness.industryALK-PositiveReceptor Protein-Tyrosine KinasesMiddle Agedmedicine.diseaseImmunohistochemistryEuropeTreatment Outcomemedicine.anatomical_structureOncology10032 Clinic for Oncology and HematologyImmunohistochemistryAdenocarcinoma2730 OncologyFemalebusiness
researchProduct

Lungscape: Resected Non–Small-Cell Lung Cancer Outcome by Clinical and Pathological Parameters

2014

INTRODUCTION: The Lungscape project was designed to address the impact of clinical, pathological, and molecular characteristics on outcome in resected non-small- cell lung cancer (NSCLC).MATERIALS AND METHODS: A decentralized biobank with fully annotated tissue samples was established. Selection criteria for participating centers included sufficient number of cases, tissue microarray building capability, and documented ethical approval. Patient selection was based on availability of comprehensive clinical data, radical resection between 2003 and 2009 with adequate follow-up, and adequate quantity and quality of formalin-fixed tissue.RESULTS: Fifteen centers contributed 2449 cases. The 5-yea…

AdultMalePulmonary and Respiratory MedicineOncologymedicine.medical_specialtyLung NeoplasmsMultivariate analysis10255 Clinic for Thoracic Surgery610 Medicine & healthNSCLCOutcome (game theory)Patients’ and pathological characteristicsYoung AdultCarcinoma Non-Small-Cell LungInternal medicinemedicineHumansPatients' and pathological characteristicsYoung adultLung cancerPathologicalAgedOutcomeAged 80 and overTNM stageTissue microarraybusiness.industryMiddle Agedmedicine.diseaseBiobankSurgeryTreatment OutcomeOncologyAnnotated Tissue2740 Pulmonary and Respiratory Medicine10032 Clinic for Oncology and Hematology2730 OncologyFemaleSurgerybusinessJournal of Thoracic Oncology
researchProduct

Dendritic Cells Ameliorate Autoimmunity in the CNS by Controlling the Homeostasis of PD-1 Receptor+ Regulatory T Cells

2012

SummaryMature dendritic cells (DCs) are established as unrivaled antigen-presenting cells (APCs) in the initiation of immune responses, whereas steady-state DCs induce peripheral T cell tolerance. Using various genetic approaches, we depleted CD11c+ DCs in mice and induced autoimmune CNS inflammation. Unexpectedly, mice lacking DCs developed aggravated disease compared to control mice. Furthermore, when we engineered DCs to present a CNS-associated autoantigen in an induced manner, we found robust tolerance that prevented disease, which coincided with an upregulation of the PD-1 receptor on antigen-specific T cells. Additionally, we showed that PD-1 was necessary for DC-mediated induction o…

Encephalomyelitis Autoimmune ExperimentalT cellProgrammed Cell Death 1 ReceptorImmunologyAntigen presentationCD11cAutoimmunity610 Medicine & healthchemical and pharmacologic phenomenaBiologymedicine.disease_causeAutoantigensT-Lymphocytes RegulatoryB7-H1 AntigenAutoimmunityImmune toleranceMiceImmune systemDownregulation and upregulationImmune TolerancemedicineAnimalsImmunology and AllergyReceptorMice KnockoutAntigen Presentation2403 Immunologyhemic and immune systemsDendritic Cells2725 Infectious DiseasesTh1 CellsCD11c AntigenMice Inbred C57BLInfectious Diseasesmedicine.anatomical_structure10032 Clinic for Oncology and HematologyImmunology2723 Immunology and AllergyTh17 CellsImmunity
researchProduct

BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

2014

BRAF-V600E expression is identified in hematopoietic progenitor and precursor myeloid dendritic cells in patients with high-risk LCH, and enforced expression of BRAF-V600E in CD11c+ cells recapitulates a high-risk LCH-like phenotype in mice.

MalePathologyendocrine system diseasesCellular differentiationCD34Antigens CD34Mice0302 clinical medicineLangerhans cell histiocytosisBone MarrowRisk FactorsImmunology and Allergyskin and connective tissue diseasesChild0303 health sciencesCell Differentiation3. Good healthHistiocytosismedicine.anatomical_structurePhenotypeTreatment Outcome030220 oncology & carcinogenesisChild PreschoolAntigens Surface2723 Immunology and AllergyFemaleProto-Oncogene Proteins B-rafmedicine.medical_specialtyImmunologyCD11c610 Medicine & healthBiologyArticle03 medical and health sciencesGermline mutationmedicineAnimalsHumansCell LineageGenetic Predisposition to DiseaseLectins C-TypeProgenitor cellneoplasms030304 developmental biology2403 ImmunologyHistocompatibility Antigens Class II302InfantCorrectionDendritic Cellsmedicine.diseaseHematopoietic Stem Cellsdigestive system diseasesCD11c Antigenenzymes and coenzymes (carbohydrates)Histiocytosis Langerhans-CellMannose-Binding Lectins10032 Clinic for Oncology and HematologyMutationBone marrowThe Journal of experimental medicine
researchProduct

Promocijas darbs

2009

Anotācija Pirmsoperācijas jeb neoadjuvantā ķīmijterapija ir ļoti cerīga vēža medikamentozās terapijas attīstības stratēģija nākotnē. Tā rada iespēju veikt krūti saglabājošu operāciju slimniecēm ar lieliem primāriem audzējiem. Slimniecēm, kurām sasniegta audzēja pilna morfoloģiska remisija pēc neoadjuvantās ķīmijterapijas operācijas materiālā, ir konstatēta garāka dzīvildze. Šī darba mērķis bija novērtēt pirmsoperācijas ķīmijterapijas, molekulāro marķieru – šūnu proliferācijas indeksa Ki-67, cilvēka epidermālā augšanas faktora receptora cerbB-2 un steroīdo hormonu receptoru lomu ārstēšanas izvēlē un bezrecidīva dzīvildzi, piecu un desmit gadu dzīvildzi slimniecēm ar lokāli izplatītu krūts vē…

Onkoloģija un hematoloģijaMedicineMedicīna un farmācijaOncology and hematologyVeselības aprūpeMedicīna
researchProduct

Saudzējoša pēcoperācijas staru terapija agrīno stadiju krūts vēža slimnieču ārstēšanā

2009

Anotācija Agrīno stadiju krūts vēža pacientēm pēc krūti saudzējošās ārstēšanas ir prognozējama liela dzīvildze, kuras laikā var manifistēties staru terapijas komplikācijas. Darba mērķis bija noteikt saudzējošās ar elpošanu sinhronizētās pēcoperācijas staru terapijas ietekmi uz vēlīno plaušu un sirds jonizējošā starojuma izraisīto komplikāciju attīstību. Standarta un saudzējošās staru terapijas metodes tika salīdzinātas pēc terapeitiskās efektivitātes, jonizējošā starojuma dozas sadalījuma riska orgānos, komplikāciju attīstības riskiem un jonizējošā starojuma dozas piegādes precizitātes. Darba rezultātā tika pierādīts, ka saudzējošā pēcoperācijas staru terapija samazina sirds un plaušu kompl…

Onkoloģija un hematoloģijaMedicineMedicīna un farmācijaOncology and hematologyVeselības aprūpeMedicīna
researchProduct

Ķīmijpreparāta cisplatīna devas noteikšana un toksicitātes prognozēšana atkarībā no pacienta taukaudu masas

2018

Darba “Ķīmijpreparāta cisplatīna devas noteikšana un toksicitātes prognozēšana atkarībā no pacienta taukaudu masas” pamatā ir veikts klīnisks pētījums. Darbā tika izvirzīta hipotēze, ka cisplatīna toksicitāte prognostiski ir saistīta ar pacientu individuālo ķermeņa taukaudu masas daudzumu un triglicerīdu līmeni asins serumā. Pētījumā piedalījās 210 personas, tajā skaitā 172 onkoloģiskie pacienti un kontroles grupa ar 38 veseliem cilvēkiem, lai validētu pētījuma metodes, kuras nevar piemērot vēža slimniekiem. Metodes. Pētījumā tika izmantotas vairākas mērījumu metodes un noteikti ķermeņa parametri. Lai analizētu cilvēka ķermeņa satvaru, īpaši akcentējot taukaudu masu, tika veikti dažādi mērī…

Onkoloģija un hematoloģijaMedicineOncology and hematologyMedicīna
researchProduct

Comment on “Worldwide Distribution of PK Deficiency: the Defect Seems Mainly Concentrated in West African Countries and the United States.”

2021

PKlcsh:RC633-647.5business.industry10031 Clinic for Angiology2720 HematologyPK DEFICIENCYDistribution (economics)610 Medicine & healthPK deficiency2725 Infectious Diseaseslcsh:Diseases of the blood and blood-forming organsHematologyUnited StatesWest African CountriesWest africanInfectious Diseases10032 Clinic for Oncology and HematologyDeficiencyMedicinebusinessSocioeconomicsLetter to the EditorMediterranean Journal of Hematology and Infectious Diseases
researchProduct